Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 12:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 119 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Best Available Treatment Clear all
Recruiting Not applicable Interventional

Preventing Suicide Among Sexual and Gender Diverse Young Adults in Primary Care

NCT05869552
View directory record Official record
Conditions
Suicide, Suicidal Ideation
Interventions
STAT-PC, YST-III
Other
Lead sponsor
Elizabeth Arnold
Other
Eligibility
18 Years to 24 Years
Enrollment
1,485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania • Austin, Texas • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 17, 2026, 12:06 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

BEhavioral Health Stratified Treatment (BEST) Study for Youth With Intellectual and/or Developmental Disabilities (IDD)

NCT05520983
View directory record Official record
Conditions
Depression, Anxiety, Transition
Interventions
Adapted Teens Achieving Mastery over Stress (TEAMS) Treatment, Adapted Teens Achieving Mastery over Stress (TEAMS) Prevention, Adapted Competent Adulthood Transition with Cognitive-behavioral & Interpersonal Training (CATCH-IT), Strengthening Families, Virtual psycho-educational discussion groups for caregivers and participants, Maternal Child Health Bureau (MCHB) Care Coordination
Behavioral · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
13 Years to 20 Years
Enrollment
780 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 12:06 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

NCT03112603
View directory record Official record
Conditions
Graft-versus-host Disease (GVHD)
Interventions
Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
38
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 17, 2026, 12:06 AM EDT
Active, not recruiting Not applicable Interventional

Acute Normovolemic Hemodilution in High Risk Cardiac Surgery Patients.

NCT03913481
View directory record Official record
Conditions
C.Surgical Procedure; Cardiac
Interventions
Acute normovolemic hemodilution, Standard care
Procedure
Lead sponsor
Università Vita-Salute San Raffaele
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 17, 2026, 12:06 AM EDT
Completed Phase 3 Interventional Results available

Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

NCT02714595
View directory record Official record
Conditions
Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP), Complicated Urinary Tract Infection (cUTI), Sepsis, Ventilator Associated Pneumonia (VAP)
Interventions
Cefiderocol, Best Available Therapy
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Hartford, Connecticut • Newark, Delaware • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 17, 2026, 12:06 AM EDT
Terminated Phase 3 Interventional Results available

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

NCT01773187
View directory record Official record
Conditions
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions
Pacritinib, Best Available Therapy
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Scottsdale, Arizona • Omaha, Nebraska • Morristown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Oct 17, 2026, 12:06 AM EDT
Active, not recruiting Not applicable Interventional

Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment

NCT05455606
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Interventions
Best Practice, Chart Abstraction, Educational Intervention, Genomic Profile, Interview, Questionnaire Administration, Tumor Board Review
Other · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
1,284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
70
States / cities
Phoenix, Arizona • Savannah, Georgia • Honolulu, Hawaii + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 17, 2026, 12:06 AM EDT
Completed Phase 2 Interventional Results available

Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19

NCT04663737
View directory record Official record
Conditions
Covid19
Interventions
Silmitasertib, SOC
Drug
Lead sponsor
Senhwa Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Gainesville, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 17, 2026, 12:06 AM EDT
Terminated Phase 2 Interventional Results available

The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation

NCT03339401
View directory record Official record
Conditions
Adenovirus
Interventions
Standard of Care, Brincidofovir
Other · Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Months to 25 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 17, 2026, 12:06 AM EDT
Terminated Phase 3 Interventional Results available

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia

NCT02055781
View directory record Official record
Conditions
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions
Pacritinib, Best Available Therapy
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
50
States / cities
Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 17, 2026, 12:06 AM EDT
Completed No phase listed Observational

Hypertension Management Using Remote Patient Monitoring: Study 2

NCT04764318
View directory record Official record
Conditions
Hypertension
Interventions
Remote patient monitoring for hypertension, Remote patient monitoring with care management
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
65 Years to 85 Years
Enrollment
17,290 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 17, 2026, 12:06 AM EDT
Not listed Phase 2Phase 3 Interventional

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

NCT03662126
View directory record Official record
Conditions
Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF)
Interventions
KRT-232, Best Available Therapy (BAT)
Drug
Lead sponsor
Kartos Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 17, 2026, 12:06 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

NCT02101268
View directory record Official record
Conditions
Primary Myelofibrosis (PMF), Post-polycythemia Vera (Post-PV), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Interventions
Momelotinib, Best Available Therapy (BAT)
Drug
Lead sponsor
Sierra Oncology LLC - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
Los Angeles, California • Gainesville, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Oct 17, 2026, 12:06 AM EDT
Recruiting Not applicable Interventional

The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema

NCT05890677
View directory record Official record
Conditions
Lymphedema, Breast Cancer
Interventions
Surgical Intervention, Conservative Complex Physical Decongestion Therapy
Procedure
Lead sponsor
University Hospital, Basel, Switzerland
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
4
States / cities
New Haven, Connecticut • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 17, 2026, 12:06 AM EDT
Recruiting Phase 2 Interventional

Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial

NCT03322995
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
First-line Chemotherapy, Second-line Chemotherapy, Chemoradiation
Drug · Radiation
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2032
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 17, 2026, 12:06 AM EDT
Recruiting Phase 1 Interventional

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

NCT05857969
View directory record Official record
Conditions
Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Large Cell Lymphoma, Refractory Childhood Acute Lymphoblastic Leukemia, Refractory Childhood Hodgkin Lymphoma, Refractory Childhood Malignant Germ Cell Neoplasm, Recurrent Childhood Brain Tumor, Recurrent Childhood Brainstem Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Ependymoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Gliosarcoma, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Childhood Malignant Solid Neoplasm, Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Malignant Neoplasm, Refractory Childhood Malignant Neoplasm
Interventions
Functional Precision Medicine
Device
Lead sponsor
Florida International University
Other
Eligibility
1 Day to 21 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 17, 2026, 12:06 AM EDT
Active, not recruiting Not applicable Interventional

SLIP II Registry: Spinal Laminectomy Versus Instrumented Pedicle Screw Fusion

NCT03570801
View directory record Official record
Conditions
Lumbar Spondylolisthesis, Grade 1 Spondylolisthesis, Lumbar Spinal Stenosis, Degenerative Spondylolisthesis
Interventions
Expert Panel Review
Other
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
16
States / cities
Scottsdale, Arizona • San Francisco, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Oct 17, 2026, 12:06 AM EDT
Completed Not applicable Interventional Results available

Financial Incentives for Smoking Cessation Among Mothers

NCT05740098
View directory record Official record
Conditions
Cigarette Smoking
Interventions
Best Practices, Financial Incentives, Nicotine Replacement Therapy
Behavioral · Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older · Female only
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 17, 2026, 12:06 AM EDT
Completed No phase listed Observational

Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.

NCT05421104
View directory record Official record
Conditions
Polycythemia Vera (PV)
Interventions
Ruxolitinib
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
1,576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 17, 2026, 12:06 AM EDT
Completed Early Phase 1 Interventional

Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma

NCT03219047
View directory record Official record
Conditions
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions
Best Practice, Ibrutinib, Patient Derived Xenograft, Personalized Medicine
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 17, 2026, 12:06 AM EDT
Not yet recruiting Not applicable Interventional

Smartphone-based Incentives Intervention to Increase Smoking Cessation During Pregnancy

NCT07840118
View directory record Official record
Conditions
Smoking During Pregnancy and Postpartum, Perinatal Cigarette Smoking
Interventions
Best Practices, Financial Incentives
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 17, 2026, 12:06 AM EDT
Completed Not applicable Interventional Results available

Suppression of HIV 1 RNA in People Living With HIV

NCT02363387
View directory record Official record
Conditions
HIV
Interventions
Incentives for Viral Suppression, Standard HIV Medical Care
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 17, 2026, 12:06 AM EDT
Completed No phase listed Observational

Registry Study for Personalized Cancer Therapy

NCT02508662
View directory record Official record
Conditions
Advanced Cancers, Solid Tumors
Interventions
Review of Screening Tests and Molecular Test Results
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 17, 2026, 12:06 AM EDT
Active, not recruiting Not applicable Interventional

Acuity 200™ (Fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear

NCT06009458
View directory record Official record
Conditions
Myopia
Interventions
Acuity 200™ (fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear
Device
Lead sponsor
Acuity Polymers, Inc.
Industry
Eligibility
7 Years and older
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
9
States / cities
Mission Viejo, California • Oakland, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 17, 2026, 12:06 AM EDT